Leczenie ewerolimusem i eksemestanem chorych na uogólnionego raka piersi w podeszłym wieku ? opis przypadku Case report
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leczenie chorych na uogólnionego raka piersi w podeszłym wieku wciąż stanowi istotny problem terapeutyczny. Zastosowanie u chorych na raka hormonozależnego, bez nadmiernej ekspresji receptora HER2, ewerolimusu w połączeniu z eksemestanem wydaje się obiecującą opcją terapeutyczną.
##plugins.generic.usageStats.downloads##
##plugins.themes.bootstrap3.article.details##
Copyright: ? Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
2. Pritchard KI, Gelmon KA, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol. 2013; 20: 48-61.
3. Baselga J, Campone M, Piccart M et al. Everolimus in Postmenopausal Hormone-Receptor?Positive Advanced Breast Cancer. N Engl J Med. 2012; 366: 520-9.
4. Paplomata E, Zelnak A, O?Regan R. Ewerolimus: side effect profile and management of toxicities in breast cancer. Future Oncol. 2012; 8(6): 651-657.
5. Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 2012; 8(6): 651-7
6. Pritchard KI, Burris HA 3rd, Ito Y et al. Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13(6): 421-432.e8.